Monitoring of BCR-ABL transcripts has become established practice in the management of chronic myeloid leukemia. However, nucleic acid amplification techniques are prone to variations which limit the reliability of real-time quantitative PCR (RQ-PCR) for clinical decision making, highlighting the need for standardization of assays and reporting of minimal residual disease (MRD) data. We evaluated a lyophilized preparation of a leukemic cell line (K562) as a potential quality control reagent. This was found to be relatively stable, yielding comparable respective levels of ABL, GUS and BCR-ABL transcripts as determined by RQ-PCR before and after accelerated degradation experiments as well as following 5 years storage at À201C. Vials of freeze-dried cells were sent at ambient temperature to 22 laboratories on four continents, with RQ-PCR analyses detecting BCR-ABL transcripts at levels comparable to those observed in primary patient samples. Our results suggest that freeze-dried cells can be used as quality control reagents with a range of analytical instrumentations and could enable the development of urgently needed international standards simulating clinically relevant levels of MRD.
Introduction
Detection of minimal residual disease (MRD) has prognostic value in many hematological malignancies, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), non-Hodgkin's lymphoma and multiple myeloma. Quantitative MRD data can be obtained with real-time quantitative PCR (RQ-PCR) analysis of immunoglobulin and T-cell receptor gene rearrangements, chromosomal breakpoint fusion region aberrations, fusion gene transcripts, or aberrantly expressed genes, depending on the type of disease. 1 A typical example of the use of RQ-PCR in onco-hematology is the monitoring of BCR-ABL transcripts in CML. In a recent international study, 70% of patients treated with imatinib achieved complete cytogenetic remission. 2 However, to evaluate the effectiveness of such treatment in more detail, a more sensitive test, such as RQ-PCR, is required. Indeed, recent studies have shown that RQ-PCR is better able to monitor the response to treatment compared to the classical cytogenetic method. [3] [4] [5] In addition, RQ-PCR-based detection of BCR-ABL in CML has become an important tool in predicting relapse after allogeneic transplant, allowing for early intervention strategies such as donor lymphocyte infusion. [6] [7] [8] [9] However, the reverse transcription RT-PCR reaction is fraught with difficulties 10 and is characterized by significant variation and lack of reproducibility between different laboratories. 11, 12 Thus, standardization and validation are necessary before routine use of an assay can occur, in order to control for interand intra-laboratory variations in results, to reduce laboratory errors and to detect critical loss of assay sensitivity. 13 Standardization can be achieved through the use of calibrated reference reagents that should be included in every assay run. Reference reagents and World Health Organization (WHO) International Standards have been established for nucleic acid amplification technique (NAT) assays for the detection of several viruses. These reference materials have been invaluable in the validation and standardization of assays for the detection of viral contamination of blood and blood products 14, 15 and therapeutic adaptation based on the blood viral load. 16 For a material to be suitable to act as an international biological reference standard, it should have reproducible performance in assays at the international level and be stable over time. Furthermore, this material needs to be suitable whatever method is used (commercial or 'in-house' reagents, using the various instruments available). In the past, efforts to standardize RQ-PCR analyses for leukemia in terms of assay design and reaction conditions have been made through the Europe Against Cancer (EAC) Program, offering a better platform to compare results between laboratories. 17, 18 The aims of the present international collaborative study, involving 22 laboratories from four continents, were to prepare an appropriate reference material for RQ-PCR testing of leukemia-associated fusion genes and to assess the suitability of such a material for standardization and validation, irrespective of the RQ-PCR machine and protocol used. The material chosen for this study was the human leukemic cell line K562, which expresses the fusion gene BCR-ABL (M-BCR, b3a2), with the majority of the laboratories using the EAC protocol. This international study was completed using data obtained in one institution (Marseille, France).
Materials and methods

Cells
CML-derived K562 cells were grown in RPMI1640 medium supplemented with 2 mM L-glutamine and 10% fetal bovine serum (Invitrogen, Cergy, France). Cells were pelleted, reformulated and lyophilized at a concentration of 3 Â 10 6 cells/ml in 5 ml glass vials (batch identified as 01/604). Each vial was filled with 1 ml cell suspension and approximately 1500 vials were filled. Vials were stored at -201C and dispatched at ambient temperature.
Plasmid DNA samples
Plasmids, containing the inserted sequences of cDNAs corresponding to control (ABL) and fusion (BCR-ABL) genes, were sent to each laboratory (kindly provided by Ipsogen, Marseille, France). These plasmids cover exons 2 and 3 of ABL and the breakpoint region of BCR-ABL M-BCR, respectively. Thus, they can be used with primers and probe sets from EAC, commercially available through Ipsogen; however, for in-house protocols or commercial kits, depending on the position of primers, the provided ABL plasmid could not be amplified in all cases. For ABL amplification, three dilutions were prepared ranging from 10 5 to 10 3 copies/5 ml. For BCR-ABL M-BCR, four dilutions were sent to each laboratory ranging from 10 5 to 10 copies/5 ml. Each vial contained 100 ml of plasmid dilution; vials were dispatched at ambient temperature and stored at -201C on receipt. Some laboratories used different calibrators to construct the BCR-ABL and ABL standard curves instead of the supplied EAC plasmid DNAs. Six laboratories used different plasmids (coded numbers 8, 9, 11, 12, 15 and 19) and one (coded number 5) used cell lines.
Comparison of lyophilized and fresh K562 cells for ABL, GUS and BCR-ABL expression
Trizol was used for extraction of RNAs from both fresh and lyophilized K562 cells. The RNA concentration was determined by measurement of the optical density at 260 nm and 1 mg of RNA was retrotranscribed following the EAC protocol. 17 The expression of control genes (ABL and GUS) and fusion transcript BCR-ABL was measured by RQ-PCR using the ABI7700 machine (ABI, Foster City, CA, USA) as previously described. 17, 18 Standard curves for quantification were created using plasmid dilutions ranging from 10 5 to 10 copies and allowed the determination of copy number (CN) for each transcript. 17 Triplicate runs for BCR-ABL and duplicate runs for ABL were performed in each assay and results expressed as the mean CN value obtained in the respective number of replicates.
Accelerated degradation studies
In order to evaluate the stability of the lyophilized reagent, vials were incubated at þ 4, þ 20, þ 37 and þ 451C (Table 2 ) at the NIBSC (UK), sent at ambient temperature and assayed in parallel with vials stored at À201C at different time points using a RQ-PCR assay for BCR-ABL, ABL and GUS transcripts in one laboratory (Marseille, France) on the ABI7700 machine according to the EAC protocol, as described above.
International evaluation -study design
Participants were sent four vials of the lyophilized K562 cells (batch 01/604) along with the plasmid dilutions described above. Participants were requested to perform four independent assays, using a fresh vial on each day. Assays for the fusion gene, BCR-ABL, and the control gene, ABL, were to be run concurrently. Standard curves for the quantification of BCR-ABL and ABL CN were to be constructed from the plasmid samples, which were to be tested in duplicate. The majority of laboratories followed the common suggested design, although some laboratories included additional triplicate runs for ABL. Raw data (C t values) for all assays and standard curves were to be returned. PCR efficiency was calculated according to the formula E ¼ 10
The samples were to be tested undiluted and at 10 À1 and 10 À2 dilutions in water, with some laboratories reporting data from a 10 À5 dilution. Throughout this report, participating laboratories are referred to by a code number allocated at random by the NIBSC statistical team, unrelated to the authorship listing order.
RQ-PCR machines used
Fourteen laboratories used the ABI 7700 (Applied Biosystems, Foster city, CA, USA) Four the Light Cycler (Roche Diagnostics, Mannheim, Germany) One the ABI 7900HT (Applied Biosystems) One the ABI 7000 (Applied Biosystems) One theABI 5700 (Applied Biosystems) One laboratory used both ABI 7900HT (Applied Biosystems) and Light Cycler (Roche).
International evaluation -assay methods
The RNA extraction protocols included use of Trizol, silicabased methods (RNeasyMini kit, Qiagen, Hilden, Germany, MagNA Pure LC mRNA from Roche Diagnostics) and CsCl gradient ultracentrifugation. RNA was retro-transcribed following EAC (10 laboratories) or other protocols (11 laboratories) and the method used was not recorded by one laboratory. Sixteen laboratories used the EAC standardized RQ-PCR protocol and primer and probes for the two genes 17, 18 which were centrally ordered (Applied Biosystems) and distributed to the participants upon request. Others used either published protocols for RQ-PCR amplification, 19 a commercial kit (Roche Diagnostics) or unpublished 'in-house' primers and probes (six laboratories).
Statistical method
For each vial and sample dilution, ABL and BCR-ABL CN were calculated using plasmid standard curves. The estimated CNs supplied by the participants were used. For each sample dilution, the geometric mean across replicate assays was calculated to give a single estimate of CN. The ratio BCR-ABL CN/ABL CN, also called normalized copy number (NCN), was expressed as a percentage.
Results
Comparison of lyophilized and fresh K562 cells for ABL, GUS and BCR-ABL expression
RNA extracted from both lyophilized and fresh K562 cells was shown to be of good quality, as determined by the Agilent 2100 bioanalyzer (Figure 1a and b) . Table 1 shows results of RQ-PCR analysis, with mean CN values calculated from seven different RT reactions for ABL, GUS and BCR-ABL. Although some variation was observed between replicate experiments, no significant differences were observed in the relative levels of the three transcripts, between fresh and lyophilized preparations of K562 cells. Table 1 Comparison of lyophilized and fresh K562 cells for fusion and control gene expression 
Analyses on stability of mRNA transcripts derived from lyophilized cells were performed in one laboratory (Marseille, France). Lyophilized K562 cells (batch 01/604) were stored from a few days to 12 months at various temperatures (Table 2 ) and for 5 years at À201C. Storage at temperatures above 41C resulted in degradation of RNA, which was not observed with material kept for 5 years at À201C (Figure 1d-g ). Nevertheless, RQ-PCR analysis revealed that BCR-ABL and control gene transcript levels were generally comparable to those detected in prestorage samples despite exposure to a range of temperatures for prolonged periods (Figure 2 ).
International study -data received
The majority of laboratories returned the cycle threshold (C t ) values and CNs of standard curves and samples as requested. The data from the standard curves (with plasmids or cell lines) supplied by the participants were analyzed in order to compare the assay performance across laboratories. Data from laboratories 11, 15 and 20 were excluded since they did not return standard curve data for ABL and/or BCR-ABL amplifications, therefore the efficiencies of RQ-PCR could not be assessed. Nine laboratories performed four independent assays with four standard curves, while 10 laboratories used the same standard curve to determinate ABL and BCR-ABL CNs in the four vials. Ninety-two standard curves were analyzed (see Supplementary  Table 1) for ABL (n ¼ 46) and BCR-ABL (n ¼ 46). Data generated by experiments with RQ-PCR efficiency lower than 90% (n ¼ 4 for ABL, n ¼ 2 for BCR-ABL and n ¼ 1 for both ABL and BCR-ABL) were excluded from further analysis. The remaining experiments (n ¼ 42 for ABL and n ¼ 43 for BCR-ABL) in this inter-laboratory setting showed a mean efficiency for ABL and BCR-ABL amplifications of 9576% and 9474%, respectively. The average slopes for ABL and BCR-ABL amplifications were À3.4570.14 and À3.4770.12, respectively.
International study -BCR-ABL DC t values and CNs BCR-ABL C t and CNs were calculated from the returned data from the analyses performed on the four neat vials and from the 1/10 dilution in water for each laboratory (see Supplementary  Table 2 for crude values: A for CN and B for NCN BCR-ABL/ ABL). Only data fulfilling our quality criteria in terms of slope, efficiency, reproducibility and RNA quality of the analyzed sample (ABL transcript CN 41000 as required by the EAC protocol 17 ) were taken into account (data not shown). The distribution of the DC t values and BCR-ABL CNs in neat and dilution 10 À1 vials are shown in Figure 3 . BCR-ABL DC t s were calculated by subtracting the mean BCR-ABL C t value of the neat vial from that of the 10 À1 dilution (Figure 3a) . Results reported by three laboratories (9, 13 and 21) for particular vials were quite discrepant from the rest of the data set, potentially indicating laboratory errors in executing the dilutions or in data reporting. The remaining results showed a mean difference of 3.2C t þ /À0.7C t between the neat and the 10 À1 dilution vials, which was very close to the DC t value equivalent to a 1Àlog difference based upon the slope of the BCR-ABL standard curve (3.45). Analysis of copy numbers showed a BCR-ABL level of 3.7 Â 10 5 76.6 Â 10 5 in the neat sample and 7.2 Â 10 4 71.5 Â 10 5 in the 10 À1 diluted sample (Figure 3b  and Supplementary Figure 1) . The observed ratio between the neat and 10 À1 sample was 8.574.2. The distribution of BCR-ABL DC t results and CNs (on the log ratio scale) appears to give a Gaussian (normal) distribution. This distribution was even accentuated when the ratios BCR ABL/ABL from the participating laboratories were used (Supplementary Figure 1) . Figure 2 RQ-PCR analysis following accelerated degradation experiments. ABL (a), GUS (b) and BCR-ABL (c) copy numbers (CNs) in lyophilized K562 cells stored from zero to 360 days at þ 41C, þ 201C, þ 371C or þ 451C. For each condition, RNA was extracted by Trizol; RT and RQ-PCR were performed following the EAC protocol. Calibrated plasmid standards were used to construct standard curves allowing determination of CN for each transcript. Horizontal lines represent the 35% variation in CN compared to t 0 which are permitted by the French Association of Normalization (AFNOR), which is a legal agency for commercial products. 
Discussion
To serve as a biological standard, it is desirable that a preparation be stable for many years. From the Arrhenius model for accelerated degradation experiments used for proteins, the estimates of potency for samples stored at elevated temperature can be used to predict the long-term stability of proteins at various temperatures. 20, 21 We applied this model to our RNA study and it was deduced that the material should be stable for at least 3 years at -201C. Although it is clear that heating the biological material altered the integrity of the total cellular RNA, as determined by the Agilent bioanalyzer (Figure 1) , the small mRNA transcripts detected by RQ-PCR remained relatively well preserved. Some variation in the relative level of BCR-ABL and the GUS control gene expression was observed between fresh and lyophilized K562 cells and in the latter following storage under different conditions. While it is possible that this reflects changes introduced in the lyophilization process and differential rates of transcript degradation, 22 inter-assay variability due to differences in the efficiency of RNA extraction, RT and PCR steps could also have made a significant contribution. Overall, these experiments clearly show that high levels of transcripts can be amplified from lyophilized cell preparations despite exposure to a wide range of ambient temperatures for prolonged periods of time.
The potential of lyophilized cell lines to provide relatively stable quality control reagents was further highlighted by the international study. Although some inter-laboratory variability was apparent, which was not unexpected and likely to reflect differences in experimental details, it is clear that shipment of lyophilized cell preparations at ambient temperature yielded RNA of sufficient quality to amplify high levels of BCR-ABL transcripts, with CN values comparable to those detected in primary patient samples. 18 This establishes a proof of principle, providing the first step towards the development of standard reagents based upon cell line dilutions that simulate clinically relevant levels of MRD. In CML, accurate detection and quantitation of BCR-ABL and control gene transcripts is fundamental to rapid identification of patients failing imatinib therapy due to resistance, who could benefit from treatment modification, in addition to directing the need for therapeutic intervention following allogeneic transplantation. [23] [24] [25] CML has provided a paradigm for molecular diagnostics and MRD monitoring, which is increasingly being applied to other subsets of leukemia to achieve a more rational treatment approach. The development of internationally recognized reference materials and external quality control rounds will be critical to ensure the reliable use of molecular diagnostics and monitoring of MRD for the appropriate management and clinical benefit of leukemia patients.
